ThromboGenics and BioInvent initiate enrollment in Phase II DVT trial
The Phase II trial is an active (enoxaparin)-controlled, dose-escalating, multicenter, prospective, randomized, open-label trial evaluating TB-402 for the prophylaxis of deep vein thrombosis (DVT) after knee surgery. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.